Enterocolitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Enterocolitis - Pipeline Review, H2 2018’, provides an overview of the Enterocolitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterocolitis

- The report reviews pipeline therapeutics for Enterocolitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Enterocolitis therapeutics and enlists all their major and minor projects

- The report assesses Enterocolitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Enterocolitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Enterocolitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Avexegen Therapeutics Inc

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

ProMetic Life Sciences Inc

Avexegen Therapeutics Inc

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

ProMetic Life Sciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Enterocolitis - Overview

Enterocolitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Enterocolitis - Overview

Enterocolitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Enterocolitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Enterocolitis - Companies Involved in Therapeutics Development

Avexegen Therapeutics Inc

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

ProMetic Life Sciences Inc

Enterocolitis - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBP-9414 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRG-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Necrotizing Enterocolitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enterocolitis - Dormant Projects

Enterocolitis - Product Development Milestones

Featured News & Press Releases

May 15, 2018: Infant Bacterial Therapeutics: Interim Management Statement, January 1 - March 31, 2018

Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins

Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)

Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants

Nov 23, 2017: Infant Bacterial Therapeutics Interim Management Statement, January 1 - September 29, 2017

Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Pediatric Investigation Plan for IBT’s lead product

Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups

Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study

Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study

Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate

Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study

Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants

Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics

Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Enterocolitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Enterocolitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2018

Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2018

Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2018

Enterocolitis - Pipeline by ProMetic Life Sciences Inc, H2 2018

Enterocolitis - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Enterocolitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Enterocolitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports